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The debate about the appropriate management of carotid
bifurcation disease not only continues but has intensified related to
a number of events over the past 18 months. These include (1)
publication of the Carotid Revascularization Endarterectomy Ver-
sus Stenting Trial (CREST) trial results, including the important
follow-up studies emphasizing the clear-cut differences in symp-
tomatic vs asymptomatic patients with regard to periprocedural
complications of stroke and death; (2) publication of multiple
guideline documents during the calendar year 2011, as reviewed
by the authors; (3) increasing emphasis in some quarters to the
claim that best/modern medical therapy is sufficient treatment (ie,
without any intervention) in asymptomatic patients; and, (4) fur-
ther considerations by the Centers for Medicare & Medicaid
Services (CMS) in the form of a CMS Medical Evidence Develop-
ment and Coverage Analysis Committee (MEDCAC) meeting
that was held January 25, 2012. The MEDCAC panel heard
testimony on multiple viewpoints from a variety of stakeholders
involved in the management of carotid disease. The Society of
Vascular Surgery (SVS) was very involved at a high level in the
CMS MEDCAC and provided its views regarding this issue.
The authors appropriately emphasize that single-specialty
practice guidelines tend to be more definitive and declarative than
those produced by consensus in multispecialty-type documents.
The authors emphasize1 the prior discussions SVS held with the
American College of Cardiology/American Heart Association
Guidelines principal authors (Drs Brott and Halperin) and the
basis of those conversations resulting in SVS endorsement of this
very comprehensive document. Just as has been true in the multi-
ple discussions about the CREST trial results, comparison of the
guideline documents reviewed by the authors is very much an “eye
of the beholder” phenomenon.
In their article, the authors cite such obfuscation when they
review, for example, a recommendation from one of the docu-
ments, which characterizes the use of carotid artery stenting (CAS)
in asymptomatic patients as “might be reasonable in highly se-
lected patients . . . , but its effectiveness compared to best medical
therapy is not well studied.” Such a recommendation is obviouslynd the subject of a highly polarizing debate among those who
old different viewpoints.
It is important to emphasize, as the authors have done, that
uidelines published in 2011 can only reflect the best available and
igh-level evidence (ie, that gleaned from well-performed, ran-
omized, clinical trials). Accordingly, the SVS guidelines support
arotid endarterectomy in properly selected asymptomatic patients
largely based on the impressive data in the Asymptomatic Carotid
urgery Trial (ACST). Alternatively, the vocal claim that optimal
odern medical therapy produces equivalent or better results is
ased on a compendium of studies from an evidence base that can
e collectively criticized as containing many patients with degrees
f asymptomatic stenosis for whom intervention would never be
ecommended by current SVS practice guidelines.
Although I agree with the authors that the guidelines they
ave reviewed can be considered to have very different recommen-
ations, they can also be considered to have very similar recom-
endations, depending on how one chooses to interpret words
ike “alternative.” At the other end of the spectrum, in asymptom-
tic patients, the United Kingdom National Institute of Health
nd Clinical Excellence guidelines, for example, unequivocally
tate that CAS for asymptomatic patients should only be per-
ormed in the context of well-designed and approved clinical trials.
No doubt, we are once again in the midst of great controversy
n the management of, in particular, asymptomatic carotid stenosis
nd the overall role of CAS. It is worth emphasizing that SVS has
dentified the management of asymptomatic carotid stenosis as its
ingle most important clinical research priority. It is also clear that
anagement of carotid disease has been a core element of vascular
urgery practice ever since the original description of the patho-
natomic relationship between carotid atherosclerosis and stroke in
951. Sixty years later, the debate continues, and vascular surgeons
ust remain involved in the study of all of these controversies
oving forward.
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